Elevated Homocysteine and C-reactive Protein Levels Independently Predict Worsening Prognosis after Stroke in Chinese Patients

被引:32
作者
Yan, Jiangtao [1 ,2 ]
Liao, James K. [3 ,4 ]
Wang, Daowen [1 ,2 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Inst Hypertens, Wuhan 430030, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Internal Med, Wuhan 430030, Peoples R China
[3] Brigham & Womens Hosp, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Boston, MA USA
关键词
homocysteine; C-reactive protein; inflammation; stroke; CORONARY-HEART-DISEASE; TRANSIENT ISCHEMIC ATTACK; CARDIOVASCULAR-DISEASE; VASCULAR-DISEASE; FOLIC-ACID; PLASMA-CONCENTRATIONS; STATIN THERAPY; RISK-FACTOR; INFLAMMATION; MARKERS;
D O I
10.1007/s11596-010-0557-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Increased plasma total homocysteine (tHcy) and high sensitivity C-reactive protein (hsCRP) levels are independent risk factors for cardiovascular disease. However, the predictive value of tHcy in combination with hsCRP in patients with stroke is not known. To determine the relationship between tHcy and hsCRP, we enrolled 291 patients with first-onset stroke (196 ischemic and 95 hemorrhagic). Plasma tHcy and hsCRP levels were measured and subsequent vascular events and deaths were determined over a 5-year period. Using the arbitrary cutoff for tHcy (< 18 mu mol/L and >= 18 mu mol/L) and hsCRP (< 1 mg/L, 1-3 mg/L and > 3 mg/L), the patients were divided into 6 groups. Survival analysis showed that the probability of death or new vascular events during a 5-year follow-up increased according to tHcy and hsCRP levels (P < 0.01). The relative risk (RR) of death or new vascular events was 4.67 (95% CI, 1.96 to 11.14, P=0.001) in patients with high tHcy (>= 18 mu mol/L) and hsCRP (> 3 mg/L) compared with those with low tHcy (< 18 mu mol/L) and hsCRP (< 1 mg/L). The increased tHcy level (>= 18 mu mol/L) combined with increased hsCRP level (> 3 mg/L) was still significantly associated with the risk of death or new vascular events (RR, 4.10, 95% CI, 1.61 to 10.45, P=0.003) even when adjusted for other risk factors at inclusion. The combination of increased tHcy and hsCRP levels had a stronger predictive value than increased hsCRP alone or increased tHcy level alone. Further studies are required to evaluate the potential decrease in risks associated with lowering both Hcy and hsCRP levels in patients that present with both increased tHcy and hsCRP.
引用
收藏
页码:643 / 647
页数:5
相关论文
共 32 条
[1]   Inflammatory bio-markers and cardiovascular risk prediction [J].
Blake, GJ ;
Ridker, PM .
JOURNAL OF INTERNAL MEDICINE, 2002, 252 (04) :283-294
[2]   Homocysteine lowering and cardiovascular events after acute myocardial infarction [J].
Bonaa, KH ;
Njolstad, I ;
Ueland, PM ;
Schirmer, H ;
Tverdal, A ;
Steigen, T ;
Wang, H ;
Nordrehaug, JE ;
Arnesen, E ;
Rasmussen, K .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (15) :1578-1588
[3]   Plasma homocysteine is a risk factor for recurrent vascular events in young patients with an ischaemic stroke or TIA [J].
Bos, MJ ;
van Goor, MLPJ ;
Koudstaal, PJ ;
Dippel, DWJ .
JOURNAL OF NEUROLOGY, 2005, 252 (03) :332-337
[4]   A QUANTITATIVE ASSESSMENT OF PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR VASCULAR-DISEASE - PROBABLE BENEFITS OF INCREASING FOLIC-ACID INTAKES [J].
BOUSHEY, CJ ;
BERESFORD, SAA ;
OMENN, GS ;
MOTULSKY, AG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (13) :1049-1057
[5]   Homocysteine and risk of ischemic heart disease and stroke -: A meta-analysis [J].
Clarke, R ;
Collins, R ;
Lewington, S ;
Donald, A ;
Alfthan, G ;
Tuomilehto, J ;
Arnesen, E ;
Bonaa, K ;
Blacher, J ;
Boers, GHJ ;
Bostom, A ;
Bots, ML ;
Grobee, DE ;
Brattström, L ;
Breteler, MMB ;
Hofman, A ;
Chambers, JC ;
Kooner, JS ;
Coull, BM ;
Evans, RW ;
Kuller, LH ;
Evers, S ;
Folsom, AR ;
Freyburger, G ;
Parrot, F ;
Genst, J ;
Dalery, K ;
Graham, IM ;
Daly, L ;
Hoogeveen, EK ;
Kostense, PJ ;
Stehouwer, CDA ;
Hopknis, PN ;
Jacques, P ;
Selhub, J ;
Luft, FC ;
Jungers, P ;
Lindgren, A ;
Lolin, YI ;
Loehrer, F ;
Fowler, B ;
Mansoor, MA ;
Malinow, MR ;
Ducimetiere, P ;
Nygard, O ;
Refsum, H ;
Vollset, SE ;
Ueland, PM ;
Omenn, GS ;
Beresford, SAA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (16) :2015-2022
[6]   C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease [J].
Danesh, J ;
Wheeler, JG ;
Hirschfield, GM ;
Eda, S ;
Eiriksdottir, G ;
Rumley, A ;
Lowe, GDO ;
Pepys, MB ;
Gudnason, V .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (14) :1387-1397
[7]   C-reactive protein in ischemic stroke - An independent prognostic factor [J].
Di Napoli, M ;
Papa, F ;
Bocola, V .
STROKE, 2001, 32 (04) :917-924
[8]   Impaired homocysteine metabolism and atherothrombotic disease [J].
Durand, P ;
Prost, M ;
Loreau, N ;
Lussier-Cacan, S ;
Blache, D .
LABORATORY INVESTIGATION, 2001, 81 (05) :645-672
[9]   Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke - a randomized substudy of the VITATOPS trial [J].
Dusitanond, P ;
Eikelboom, JW ;
Hankey, GJ ;
Thom, J ;
Gilmore, G ;
Loh, K ;
Yi, Q ;
Klijn, CJM ;
Langton, P ;
van Bockxmeer, FM ;
Baker, R ;
Jamrozik, K .
STROKE, 2005, 36 (01) :144-146
[10]   Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence [J].
Eikelboom, JW ;
Lonn, E ;
Genest, J ;
Hankey, G ;
Yusuf, S .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (05) :363-375